Login to Your Account

Phase IIb Gastroparesis Data Devastate; Tranzyme Falls 76%

By Catherine Shaffer
Staff Writer

Thursday, November 15, 2012
Shares of Tranzyme Pharma Inc. plunged on release of top-line results from the first of two Phase IIb trials of its gastroparesis candidate, TZP-102, showing that it did not meet its primary efficacy endpoint at either tested dose.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription